In this Issue
Lykos CEO Provides AdComm Feedback to FDA Commissioner
Cybin Plans to Fight Functional Unblinding with ‘Firewall’
Doblin Charts a Future for MAPS • DEA Plots Ketamine Crackdown
Colorado Closes First Round of Rulemaking for State Psychedelics Program.
Other Stories, including: MindMed’s Phase 3 program; upcoming FDA-affiliated event on PTSD treatments.
***
Lykos CEO Provides AdComm Feedback to FDA Commissioner
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Subscribe AnnuallySubscribe Monthly
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space✓ Regular articles and deep dives across psychedelic research, policy and business✓ Interviews with insiders✓ Monthly interactive database and commentary on psychedelic patents✓ Quick-take analysis of major developments✓ A Library of primers and explainers✓ Access to our full back catalogue
Learn more about Pα+
